NAGIOS: RODERIC FUNCIONANDO

SGLT2i and GLP-1RA in cardiometabolic and renal diseases : from glycemic control to adipose tissue inflammation and senescence

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

SGLT2i and GLP-1RA in cardiometabolic and renal diseases : from glycemic control to adipose tissue inflammation and senescence

dc.contributor.author	D'Marco, Luis
dc.contributor.author	Morillo, Valery
dc.contributor.author	Górriz Teruel, Jose Luis
dc.contributor.author	Suarez, María K.
dc.contributor.author	Nava, Manuel
dc.contributor.author	Ortega, Ángel
dc.contributor.author	Parra, Heliana
dc.contributor.author	Villasmil, Nelson
dc.contributor.author	Rojas Quintero, Joselyn
dc.contributor.author	Bermúdez, Valmore
dc.date.accessioned	2022-06-15T16:43:41Z
dc.date.available	2022-06-15T16:43:41Z
dc.date.issued	2021
dc.identifier.citation	D'Marco, Luis Morillo, Valery Górriz Teruel, Jose Luis Suarez, María K. Nava, Manuel Ortega, Ángel Parra, Heliana Villasmil, Nelson Rojas Quintero, Joselyn Bermúdez, Valmore 2021 SGLT2i and GLP-1RA in cardiometabolic and renal diseases : from glycemic control to adipose tissue inflammation and senescence Journal Of Diabetes Research
dc.identifier.uri	https://hdl.handle.net/10550/83162
dc.description.abstract	Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addition to being used for glycemic control in diabetic patients, these drugs also have other favorable effects such as weight loss and lowering blood pressure, and more recently, they have been shown to have cardio and renoprotective effects with anti-inflammatory properties. Concerning the latter, the individual or associated use of these antihyperglycemic agents has been linked with a decrease in proinflammatory cytokines and with an improvement in the inflammatory profile in chronic endocrine-metabolic diseases. Hence, these drugs have been positioned as first-line therapy in the management of diabetes and its multiple comorbidities, such as obesity, which has been associated with persistent inflammatory states that induce dysfunction of the adipose tissue. Moreover, other frequent comorbidities in long-standing diabetic patients are chronic complications such as diabetic kidney disease, whose progression can be slowed by SGLT2i and/or GLP-1RA. The neuroendocrine and immunometabolism mechanisms underlying adipose tissue inflammation in individuals with diabetes and cardiometabolic and renal diseases are complex and not fully understood. Summary. This review intends to expose the probable molecular mechanisms and compile evidence of the synergistic or additive anti-inflammatory effects of SGLT2i and GLP-1RA and their potential impact on the management of patients with obesity and cardiorenal compromise.
dc.language.iso	eng
dc.relation.ispartof	Journal Of Diabetes Research, 2021
dc.subject	Cor Malalties
dc.subject	Ronyons
dc.subject	Diabetis
dc.title	SGLT2i and GLP-1RA in cardiometabolic and renal diseases : from glycemic control to adipose tissue inflammation and senescence
dc.type	journal article	es_ES
dc.date.updated	2022-06-15T16:43:41Z
dc.identifier.doi	10.1155/2021/9032378
dc.identifier.idgrec	154217
dc.rights.accessRights	open access	es_ES